11 Best GLP-1 and Weight Loss Stocks to Invest in

2. Pfizer Inc. (NYSE:PFE)

Number of Hedge Fund Holders: 99

Pfizer Inc. (NYSE:PFE) reported positive topline results from its Phase 3 BASIS study, which evaluated HYMPAVZI™ (marstacimab) in patients with hemophilia A or B with inhibitors.

The annualized bleeding rate was reduced by 93% with once-weekly subcutaneous medication as opposed to on-demand intravenous treatment (1.39 vs. 19.78; p < 0.0001). Furthermore, HYMPAVZI was superior in all secondary endpoints linked to bleeding and was usually well-tolerated; no thromboembolic events or fatalities were observed.

HYMPAVZI was investigated in 48 patients over 12 months, with a focus on a high-need population: 20% of hemophilia A and 3% of hemophilia B patients develop inhibitors that negate traditional factor replacement therapy. Pfizer Inc. (NYSE:PFE) developed the treatment, which functions by blocking the tissue factor pathway inhibitor instead of substituting FVIII or FIX. HYMPAVZI, which is administered using a pre-filled pen, provides patients with few other options with a straightforward preventative approach. Pfizer Inc. (NYSE:PFE) will begin regulatory filings after conducting a thorough data review. It is among the Best Weight Loss Stocks.